ArticleCPT: pharmacometrics & systems pharmacology2012
Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics.
Article in CPT: pharmacometrics & systems pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.British journal of clinical pharmacology · 2015Trial
- An Innovative Multifaceted Approach to Enhance the Sensitivity of a Target Engagement ELISA.Pharmaceutical research · 2026Article
- Article
- A model-based approach using GSK3772847, an anti-interleukin-33 receptor monoclonal antibody, as a showcase to predict SC administration PK and free target dynamics based on PK and total target measurements after IV administration.CPT: pharmacometrics & systems pharmacology · 2025Article
- The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases.Pharmaceutics · 2024Review
- Best Practices in mAb and Soluble Target Assay Selection for Quantitative Modelling and Qualitative Interpretation.The AAPS journal · 2023Article
- Ultra-Low Dose Cytokines in Rheumatoid Arthritis, Three Birds with One Stone as the Rationale of the 2LARTHInternational journal of molecular sciences · 2021Review
- Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications.Clinical pharmacokinetics · 2020Review
- Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases.Nature reviews. Rheumatology · 2020Review
- Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.Clinical pharmacokinetics · 2019Review
- Canakinumab for refractory RA: a case report.Mediterranean journal of rheumatology · 2018Article
- Review
- Deciphering the In Vivo Performance of a Monoclonal Antibody to Neutralize Its Soluble Target at the Site of Action in a Mouse Collagen-Induced Arthritis Model.Pharmaceutical research · 2016Article
- Exposure-response modeling of clinical end points using latent variable indirect response models.CPT: pharmacometrics & systems pharmacology · 2014Article
- A mathematical analysis of rebound in a target-mediated drug disposition model: I.without feedback.Journal of mathematical biology · 2014Article
- Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.The AAPS journal · 2014Article
- Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development.The AAPS journal · 2013Article
- CPT: Pharmacometrics and Systems Pharmacology.CPT: pharmacometrics & systems pharmacology · 2012Article
- Off-label use of anti-IL-1 drugs in rheumatic diseases.International journal of immunopathology and pharmacologyArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Canakinumab, an anti-interleukin-1β (IL-1β) monoclonal antibody, is approved for cryopyrin-associated periodic syndromes and is under investigation for the management of other inflammatory disorders. In this study, population-based pharmacokinetic-pharmacodynamic models were developed to understand responses to canakinumab in patients with rheumatoid arthritis (RA). Total canakinumab and total IL-1β concentrations were obtained from four clinical trials (n = 472). In contrast to traditional models, free IL-1β concentrations were calculated and used to link canakinumab to changes in C-reactive protein (CRP) concentrations and American College of Rheumatology (ACR) scores of 20, 50, and 70% improvement. Temporal patterns of total canakinumab, total IL-1β, CRP, and ACR scores were all well described. Simulations confirmed that 150 mg every 4 weeks improved ACR scores in patients with RA, but no additional benefit was provided by higher doses or more frequent administration. Integrating predicted endogenous free ligand concentrations with biomarkers and clinical outcomes could be extended to new therapies of anti-inflammatory diseases.CPT: Pharmacometrics & Systems Pharmacology (2012) 1, e5; doi:10.1038/psp.2012.6; advance online publication 26 September 2012.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.